Company intelligence / Profile preview

Serpin Pharma

Manassas, Virginia, United Statesserpinpharma.com ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

In AMI, a single SP16 injection preserved heart function, reduced infarcts, and decreased biomarkers of cardiac injury. SP16 is currently undergoing pre-clinical and clinical trials for a broad span of orphan, chronic, and acute indications.

Therapeutic areas: GastroenterologyImmunologyCardiovascularDermatology
Modalities: Synthetic peptideTherapeutic protein
Industry: Biotech

Drug pipeline

9 assets

SP16

8 more assets in the full pipeline.

Request access →

Partnerships

The Estée Lauder Companies (announced February 26, 2025)

Beyond the preview

Go deeper on Serpin Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serpin Pharma.

Explore the full profile